bradlessard

[Acer Therapeutics @AcerTherapeutic]

Acer Therapeutics’ OLPRUVA™ update: preliminary launch activities progressing; building out commercial and medical affairs teams to support U.S. launch in Q2 2023, with drug availability anticipated by early July 2023 https://t.co/JCYLSMCw3P

[Acer Therapeutics @AcerTherapeutic]

Acer Therapeutics announces presentation of HCP Urea Cycle Disorder treatment preference data at the Society for Inherited Metabolic Disorders (#SIMD) Annual Meeting and provides OLPRUVA™ program update https://t.co/JCYLSMCw3P